This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
The Science Committee is committed to presenting the best neuroscientific research at the Annual Meeting and is pleased to share the following 23 abstracts presented as part of the Emerging Science program. Each Emerging Science abstract qualified by having key aspects of research conducted after the October 23, 2017, abstract submission deadline. They are new and of sufficient scientific importance to warrant expedited presentation and publication.
- Received April 13, 2018.
- Accepted in final form April 13, 2018.
- © 2018 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
- Article
- INTREPID: A prospective, double-blinded, multicenter randomized controlled trial evaluating deep brain stimulation with a new multiple-source, constant-current rechargeable system in Parkinson's disease
- ABX-1431, a first-in-class endocannabinoid modulator, improves tics in adult patients with Tourette syndrome
- Longer-term assessment of the safety and efficacy of nusinersen for the treatment of infantile-onset spinal muscular atrophy: An interim analysis of the SHINE study
- RG7916 significantly increases SMN protein in SMA type 1 babies
- Effect of fingolimod in pediatric MS: further insights from sensitivity, supportive, and post hoc analyses from PARADIGMS
- MRI and relapse results for ALKS 8700 in patients with relapsing-remitting multiple sclerosis: 1-Year interim results from the phase 3 EVOLVE-MS-1 study
- Ezutromid significantly reduced muscle damage whilst maintaining utrophin in patients with Duchenne muscular dystrophy after 24 weeks of treatment
- Efficacy, safety, and tolerability of ubrogepant for the acute treatment of migraine: Results from a single-attack phase II study, ACHIEVE I
- Efficacy and safety of erenumab in episodic migraine patients with 2–4 prior preventive treatment failures: Results from the phase 3b LIBERTY study
- AVXS-101 gene replacement therapy for SMA type 1: Pivotal study (STR1VE) update
- Effect of ZX008 (fenfluramine HCl oral solution) on total seizures in Dravet syndrome
- Transdermal cannabidiol (CBD) gel for the treatment of focal epilepsy in adults
- ZX008 (fenfluramine HCL oral solution) in Dravet syndrome: Effect on convulsive seizure frequency in subjects who failed treatment with stiripentol prior to study 1
- Eptinezumab achieved meaningful reductions in migraine activity as early as day 1 and were sustained through week 12: Results from PROMISE-2 (Prevention of Migraine via Intravenous Eptinezumab Safety and Efficacy–2) phase 3 trial in chronic migraine
- Eptinezumab reduced migraine frequency and triptan/ergotamine use over weeks 1–12, and improved HIT-6 scores at months 1 and 3: Results from the phase 3 PROMISE-2 trial in chronic migraine
- Clinical development of VX15/2503 anti-semaphorin 4D antibody as a potential treatment for Huntington disease
- A randomized trial of deferiprone for pantothenate kinase–associated neurodegeneration (on behalf of the TIRCON group)
- Noninvasive peripheral nerve stimulation for symptomatic relief of hand tremor in essential tremor
- Natalizumab extended interval dosing is associated with a significant reduction in progressive multifocal leukoencephalopathy risk compared with standard interval dosing in the TOUCH® prescribing program
- Autologous haematopoietic stem cell transplantation in treatment-naive patients with aggressive multiple sclerosis
- B-cell targeted treatment in myasthenia gravis (BeatMG): A phase 2 trial of rituximab in myasthenia gravis: Topline results
- A double-blind placebo-controlled study to evaluate the safety and efficacy of FcRn antagonist ARGX-113 (efgartigimod) in generalized myasthenia gravis
- A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of eptinezumab for the preventive treatment of chronic migraine: Results of the PROMISE-2 (Prevention of Migraine via Intravenous Eptinezumab Safety and Efficacy 2) trial
- Info & Disclosures
